Quest Diagnostics (DGX) Stock Forecast & Price Target

Compare

928 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DGX Analyst Ratings

Moderate Buy

7 Buy

7 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Quest

Diagnostics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DGX Stock 12 Month Forecast

Average Price Target

$188.83

▲(8.31%Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Quest Diagnostics in the last 3 months. The average price target is $188.83 with a high forecast of $200.00 and a low forecast of $175.00. The average price target represents a 8.31% change from the last price of $174.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"133":"$133","150":"$150","167":"$167","184":"$184","201":"$201"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":188.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$188.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":175,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$175.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[133,150,167,184,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.32,179.06461538461537,180.80923076923077,182.55384615384614,184.29846153846154,186.0430769230769,187.7876923076923,189.53230769230768,191.27692307692308,193.02153846153846,194.76615384615386,196.51076923076923,198.25538461538463,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.32,178.20538461538462,179.09076923076924,179.97615384615384,180.86153846153846,181.74692307692308,182.6323076923077,183.5176923076923,184.40307692307692,185.28846153846155,186.17384615384617,187.05923076923077,187.9446153846154,{"y":188.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.32,177.14153846153846,176.96307692307693,176.7846153846154,176.60615384615383,176.4276923076923,176.24923076923076,176.07076923076923,175.8923076923077,175.71384615384616,175.5353846153846,175.35692307692307,175.17846153846153,{"y":175,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":134.82,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.15,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.37,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.7,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.06,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":168.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$200.00

Average Price Target$188.83

Lowest Price Target$175.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Erin WrightMorgan Stanley

Morgan Stanley

$182

Buy

4.39%

Upside

Reiterated

05/23/25

Quest Diagnostics: Strong Growth Prospects and Strategic Initiatives Drive Buy Rating

Lisa GillJ.P. Morgan

J.P. Morgan

$180→$190

Hold

8.98%

Upside

Reiterated

05/06/25

Analysts Conflicted on These Healthcare Names: Biomea Fusion (NASDAQ: BMEA) and Quest Diagnostics (NYSE: DGX)

Patrick B DonnellyCiti

Citi

$185

Hold

6.11%

Upside

Reiterated

05/06/25

Quest Diagnostics: Balancing Strong Q1 Performance with Moderate Future Growth Outlook

David WestenbergPiper Sandler

Piper Sandler

$180→$200

Hold

14.72%

Upside

Reiterated

04/28/25

Quest Diagnostics (DGX) Gets a Hold from Piper Sandler

David S MacdonaldTruist Financial

Truist Financial

―

Hold

―

Reiterated

04/23/25

Truist Financial Keeps Their Hold Rating on Quest Diagnostics (DGX)

Eric ColdwellRobert W. Baird

Robert W. Baird

$191→$194

Buy

11.28%

Upside

Reiterated

04/23/25

Quest Diagnostics price target raised to $194 from $191 at BairdQuest Diagnostics price target raised to $194 from $191 at Baird

Luke SergottBarclays

Barclays

$175→$185

Hold

6.11%

Upside

Reiterated

04/23/25

Quest Diagnostics (DGX) Gets a Hold from Barclays

Michael ChernyLeerink Partners

Leerink Partners

$184→$189

Buy

8.41%

Upside

Reiterated

04/22/25

Quest Diagnostics: Strong Growth Potential and Resilience Amidst Economic Uncertainty

Michael RyskinBank of America Securities

Bank of America Securities

$198

Buy

13.57%

Upside

Reiterated

04/22/25

Quest Diagnostics: Resilience and Growth Potential Amidst Macroeconomic Challenges

Andrew BrackmannWilliam Blair

William Blair

―

Buy

―

Reiterated

04/22/25

Quest Diagnostics: Strong Q1 Performance and Positive Outlook Support Buy Rating

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$175

Hold

0.38%

Upside

Reiterated

04/22/25

Evercore ISI Sticks to Its Hold Rating for Quest Diagnostics (DGX)

Ann HynesMizuho Securities

Mizuho Securities

$178→$189

Buy

8.41%

Upside

Reiterated

04/09/25

Quest Diagnostics price target raised to $189 from $178 at MizuhoQuest Diagnostics price target raised to $189 from $178 at Mizuho

Jamie ClarkRedburn Atlantic

Redburn Atlantic

$195

Buy

11.85%

Upside

Initiated

04/02/25

Quest Diagnostics initiated with a Buy at Redburn AtlanticQuest Diagnostics initiated with a Buy at Redburn Atlantic

Jack MeehanNephron

Nephron

$184

Hold

5.54%

Upside

Downgraded

03/27/25

Nephron downgrades Quest Diagnostics (DGX) to HoldNephron analyst Jack Meehan downgraded Quest Diagnostics (NYSE: DGX) from Buy to Hold with a price target of $184.00.

Kevin CaliendoUBS

UBS

$166→$170

Hold

-2.49%

Downside

Reiterated

02/03/25

Quest Diagnostics (DGX) PT Raised to $170 at UBSUBS analyst Kevin Caliendo raised the price target on Quest Diagnostics (NYSE: DGX) to $170.00 (from $166.00) while maintaining a Neutral rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Erin WrightMorgan Stanley

Morgan Stanley

$182

Buy

4.39%

Upside

Reiterated

05/23/25

Quest Diagnostics: Strong Growth Prospects and Strategic Initiatives Drive Buy Rating

Lisa GillJ.P. Morgan

J.P. Morgan

$180→$190

Hold

8.98%

Upside

Reiterated

05/06/25

Analysts Conflicted on These Healthcare Names: Biomea Fusion (NASDAQ: BMEA) and Quest Diagnostics (NYSE: DGX)

Patrick B DonnellyCiti

Citi

$185

Hold

6.11%

Upside

Reiterated

05/06/25

Quest Diagnostics: Balancing Strong Q1 Performance with Moderate Future Growth Outlook

David WestenbergPiper Sandler

Piper Sandler

$180→$200

Hold

14.72%

Upside

Reiterated

04/28/25

Quest Diagnostics (DGX) Gets a Hold from Piper Sandler

David S MacdonaldTruist Financial

Truist Financial

―

Hold

―

Reiterated

04/23/25

Truist Financial Keeps Their Hold Rating on Quest Diagnostics (DGX)

Eric ColdwellRobert W. Baird

Robert W. Baird

$191→$194

Buy

11.28%

Upside

Reiterated

04/23/25

Quest Diagnostics price target raised to $194 from $191 at BairdQuest Diagnostics price target raised to $194 from $191 at Baird

Luke SergottBarclays

Barclays

$175→$185

Hold

6.11%

Upside

Reiterated

04/23/25

Quest Diagnostics (DGX) Gets a Hold from Barclays

Michael ChernyLeerink Partners

Leerink Partners

$184→$189

Buy

8.41%

Upside

Reiterated

04/22/25

Quest Diagnostics: Strong Growth Potential and Resilience Amidst Economic Uncertainty

Michael RyskinBank of America Securities

Bank of America Securities

$198

Buy

13.57%

Upside

Reiterated

04/22/25

Quest Diagnostics: Resilience and Growth Potential Amidst Macroeconomic Challenges

Andrew BrackmannWilliam Blair

William Blair

―

Buy

―

Reiterated

04/22/25

Quest Diagnostics: Strong Q1 Performance and Positive Outlook Support Buy Rating

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$175

Hold

0.38%

Upside

Reiterated

04/22/25

Evercore ISI Sticks to Its Hold Rating for Quest Diagnostics (DGX)

Ann HynesMizuho Securities

Mizuho Securities

$178→$189

Buy

8.41%

Upside

Reiterated

04/09/25

Quest Diagnostics price target raised to $189 from $178 at MizuhoQuest Diagnostics price target raised to $189 from $178 at Mizuho

Jamie ClarkRedburn Atlantic

Redburn Atlantic

$195

Buy

11.85%

Upside

Initiated

04/02/25

Quest Diagnostics initiated with a Buy at Redburn AtlanticQuest Diagnostics initiated with a Buy at Redburn Atlantic

Jack MeehanNephron

Nephron

$184

Hold

5.54%

Upside

Downgraded

03/27/25

Nephron downgrades Quest Diagnostics (DGX) to HoldNephron analyst Jack Meehan downgraded Quest Diagnostics (NYSE: DGX) from Buy to Hold with a price target of $184.00.

Kevin CaliendoUBS

UBS

$166→$170

Hold

-2.49%

Downside

Reiterated

02/03/25

Quest Diagnostics (DGX) PT Raised to $170 at UBSUBS analyst Kevin Caliendo raised the price target on Quest Diagnostics (NYSE: DGX) to $170.00 (from $166.00) while maintaining a Neutral rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Quest Diagnostics

1 Month

xxx

Success Rate

17/35 ratings generated profit

Average Return

+1.12%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 48.57% of your transactions generating a profit, with an average return of +1.12% per trade.

3 Months

xxx

Success Rate

11/17 ratings generated profit

Average Return

+4.52%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +4.52% per trade.

1 Year

Eric ColdwellRobert W. Baird

Success Rate

14/17 ratings generated profit

Average Return

+10.18%

reiterated a buy rating 2 months ago

Copying Eric Coldwell's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +10.18% per trade.

2 Years

xxx

Success Rate

16/17 ratings generated profit

Average Return

+16.09%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +16.09% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DGX Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DGX has received 18 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. DGX average Analyst price target in the past 3 months is 188.83.

Each month's total comprises the sum of three months' worth of ratings.

DGX Financial Forecast

DGX Earnings Forecast

Next quarter’s earnings estimate for DGX is $2.57 with a range of $2.53 to $2.69. The previous quarter’s EPS was $2.21. DGX beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.04% of the time in the same period. In the last calendar year DGX has Outperformed its overall industry.

DGX Sales Forecast

Next quarter’s sales forecast for DGX is $2.73B with a range of $2.70B to $2.79B. The previous quarter’s sales results were $2.65B. DGX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 40.00% of the time in the same period. In the last calendar year DGX has Outperformed its overall industry.

DGX Stock Forecast FAQ

What is DGX’s average 12-month price target, according to analysts?

Based on analyst ratings, Quest Diagnostics’s 12-month average price target is 188.83.

What is DGX’s upside potential, based on the analysts’ average price target?

Quest Diagnostics has 8.31% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DGX a Buy, Sell or Hold?

Quest Diagnostics has a consensus rating of Moderate Buy which is based on 7 buy ratings, 7 hold ratings and 0 sell ratings.

What is Quest Diagnostics’s price target?

The average price target for Quest Diagnostics is 188.83. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $200.00 ,the lowest forecast is $175.00. The average price target represents 8.31% Increase from the current price of $174.34.

What do analysts say about Quest Diagnostics?

Quest Diagnostics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of DGX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Quest Diagnostics (DGX) Stock Forecast & Price Target

DGX Analyst Ratings

DGX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Quest Diagnostics

DGX Analyst Recommendation Trends

DGX Financial Forecast

DGX Earnings Forecast

DGX Sales Forecast

DGX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts